Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXA127 for aGVHD prevention in PBSCT
NCT01882387Phase 2Withdrawn
- Sponsor
- Tarix Pharmaceuticals Ltd.
- Start
- Dec 2013
- Primary completion
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of talfirastide in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Tarix Pharmaceuticals Ltd.. Planned start Dec 2013; status: withdrawn.
02
Drugs
talfirastide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT01882387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01882387.